Zynerba Pharmaceuticals of Devon announced Monday morning that it had won the status for its Zygel transdermal CBD lotion. Fast Track designation speeds up the review of drugs that treat an unmet medical need. There currently are no drugs to treat the symptoms of Fragile X syndrome, which include developmental problems from learning disabilities to cognitive impairment. Zynerba is in the final stages of a clinical trial of Zygel and hopes to have it on the market by late 2020, said spokesman Will Roberts.
Thank you for reading this article! We’d love to hear your thoughts and answer your questions in the comments below.